High CV risk in young people is a 'delayed' crisis

Published Date: 08 Mar 2023

Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.

Read Full News

Latest News

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD Neal Bhatia, MD

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA Killian Lozach, MBA

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Tips on Optimizing HS Biologics, Combinations, and Surgery

Tips on Optimizing HS Biologics, Combinations, and Surgery

Conference Preview: Fall Clinical Dermatology Conference 2026

Conference Preview: Fall Clinical Dermatology Conference 2026

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Latest News

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Tips on Optimizing HS Biologics, Combinations, and Surgery

Conference Preview: Fall Clinical Dermatology Conference 2026

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

News All Time

7 Dermatology Headlines You Missed in September 2026

7 Dermatology Headlines You Missed in September 2026

EADV Congress 2026: Day 2 Recap—6 Headlines to Know

EADV Congress 2026: Day 2 Recap—6 Headlines to Know

What the FDA's Approval of Ameluz PDT Means for Skin Cancer Neal Bhatia, MD

What does FDA approval of Ameluz PDT for superficial BCC mean for dermatology? Neal Bhatia, MD, weighs in on the first-of-its-kind decision.

EADV Congress 2026: Day 1 Recap — 6 Headlines to Know Victoria Johnson

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

FDA News Recap: Novel Drug Approvals in Q3 2026

FDA News Recap: Novel Drug Approvals in Q3 2026

NB-UVB Plus Upadacitinib Yields Higher Vitiligo Repigmentation Rates

NB-UVB Plus Upadacitinib Yields Higher Vitiligo Repigmentation Rates

EADV 2026: Tilrekimig Achieves EASI-75 Across All Doses in Atopic Dermatitis

EADV 2026: Tilrekimig Achieves EASI-75 Across All Doses in Atopic Dermatitis

Nail Detachment 4 Times More Common With GLP-1 Use

Nail Detachment 4 Times More Common With GLP-1 Use

Key Lessons in Leadership as a Clinician, With Kristina Duffin, MD Kristina Duffin, MD

Kristina Duffin, MD, MS, shares lessons from her LEADderm leadership session, including how to define which problems are truly yours to solve.

APEX Part B: Zumilokibart Achieves Primary Endpoint in Atopic Dermatitis Tim Smith

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

CUPID A and C: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU Tim Smith

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

Climate Change Tied to Skin Disease Worsening in 42% of Countries

Climate Change Tied to Skin Disease Worsening in 42% of Countries

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

The Present and Future of Precision Medicine in Dermatology, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, discusses why precision medicine has advanced further in psoriasis than atopic dermatitis, and what oncology can teach dermatology.

Recommended News For You

GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer

An individual state lost $4.02 billion due to untreated mental illness.

Including Isatuximab with a Standard Backbone Enhances Multiple Myeloma Results.

The Early Progression of Prostate Cancer Is Not Stopped by Metformin.

Squeezing through tiny blood vessels may trigger melanoma cells to spread

Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.

The pandemic had little impact on mental health symptoms.

Recommended Articles For You

Transformative Directions in Hematology in Clinical Decision-Making 

The Role of Calcium Corrections in Accurate Blood Test Results  

Nipple-Sparing Mastectomy: Oncologic Safety and Patient Selection Review 

Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

2.

Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

3.

Weight loss trial reports success for breast cancer patients at one year mark

4.

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

5.

Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patients

1.

Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers

2.

Single-Cell Lineage Tracing in Hematology: Decoding the Cellular Blueprint of Blood Disorders

3.

AI-Powered Strategies for Precision and Improved Outcomes in Esophageal Cancer, a Global Health Crisis

4.

Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential

5.

Epigenetic Subtyping of Complex Hematologic Disorders

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

Updates on the First Line Management of ALK+ NSCLC

2.

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients

3.

Navigating the Complexities of Ph Negative ALL - Part V

4.

Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II

5.

Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot